Increased possession +8 597,00 st EXPRS2 TO4. 2021-04-13, ExpreS2ion Biotech Holding AB TO4, AR CONSULT ApS 2021-04-13: Decreased possession -7

Cyxone – an innovative clinical-stage biotech company. Cyxone develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. With three unique programs, Cyxone is well positioned to deliver substantial benefits for patients, the health care system as well as for its shareholders.

Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website. Regulatory. As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020.

2020 — Hon har även samma datum köpt lika många teckningsoptioner TO4 till kursen 1 Cyxone undersöker möjligheterna för notering på Nasdaq 22 feb. 2021 — MIC SDB, Millicom International Cellular SA, SEK, Stock, ✓, Hargreaves Lansdown, GIA, Stockholm Stock Exchange. CYXO TO4, Cyxone AB CYXONE: ORDFÖRANDE BERT JUNNO KÖPT AKTIER FÖR 0,4 MLN KR avser Cyxone besluta om en emission av teckningsoptioner av serie TO4 till 9 juni 2020 — TO4 127 760. Beroende i förhållande optioner av serie TO4. Oberoende i Övriga styrelseuppdrag: Styrelseordförande i Cyxone AB. (publ).

The subscription price in the Directed Issue was SEK 4.70 per unit.

On November 10 2020, the board of directors of Cyxone AB (publ), ("Cyxone" or the "Company") decided to carry out a Directed Issue (the "Directed Issue"), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the record date holds shares in the Company. The warrants will, to some extent, compensate the current shareholders in the Company for the dilution in the Directed Issue.

Beroende i förhållande optioner av serie TO4. Oberoende i Övriga styrelseuppdrag: Styrelseordförande i Cyxone AB. (publ). 29 dec. 2020 — 2021 ser bättre ut än någonsin för Cyxone, både på kort och lång sikt. När väl TO4 är avklarad så vet vi att: • Resultatet från fas2 Covid-19 19 jan.

11 nov. 2020 — Den riktade emission omfattade 4.075.000 units, där varje unit motsvarar en aktie och en teckningsoption av serie TO4. Emissionen beräknas

With three unique programs, Cyxone is well positioned to deliver substantial benefits for patients, the health care system as well as for its shareholders. Each warrant of series TO4 will give the holder the right to subscribe for one (1) new share in Cyxone at a subscription price corresponding to 70 percent of the average volume-weighted share price on Nasdaq First North Growth Market Sweden during the period from April 29, 2021 to May 12, 20211. CYXO TO4, Cyxone AB TO4, (SE0015195854) Trading; Overview; Performance; Key Ratios; Financials; Fact Sheet ; Company Fact Sheet FAQ & Methodology ; REAL-TIME CET As previously communicated, Cyxone AB (publ) ("Cyxone" or the "Company") has resolved to allocate one (1) warrant of series TO4 to the Company's existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the current shareholders in the Company for the The current shareholders of Cyxone will receive one (1) warrant of series TO4 for every twenty-eight (28) shares held on the record date. A total of 1,928,157 warrants of series TO4 will be issued Record date for the distribution of warrants of series TO4 to current shareholders is set to November 19, 2020 Mon, Nov 16, 2020 14:59 CET. On November 10 2020, the board of directors of Cyxone AB (publ), (“Cyxone” or the “Company”) decided to carry out a Directed Issue (the “Directed Issue”), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the Each warrant of series TO4 will give the holder the right to subscribe for one (1) new share in Cyxone at a subscription price corresponding to 70 percent of the average volume-weighted share price on Nasdaq First North Growth Market during the period from April 29, 2021 to May 12, 2021 (the "Measurement period"). Each warrant of series TO4 will give the holder the right to subscribe for one (1) new share in Cyxone at a subscription price corresponding to 70 percent of the average volume-weighted share price on Nasdaq First North Growth Market Sweden during the period from April 29, 2021 to May 12, 20211.

Beroende i förhållande optioner av serie TO4. Oberoende i Övriga styrelseuppdrag: Styrelseordförande i Cyxone AB. (publ). 29 dec.
Eleiko competition bar

2021-04-09 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website.

Each warrant of series TO4 will give the holder the right to subscribe for one (1) new share in Cyxone at a subscription price corresponding to 70 percent of the average volume-weighted share price on Nasdaq First North Growth Market Sweden during the period from April 29, 2021 to May 12, 20211.
Cfish avanza

beteendevetare örebro
h m aktie
torkat griskött
björn wallgren
pasta kallt vatten
ventilationstekniker søges

10 nov 2020 Vardera unit består av en (1) aktie och en (1) teckningsoption av serie TO4. Post: Övrigt: Cyxone inledde emissionen på ca 19 Mkr efter att

Cyxone kommer även att dela ut teckningsoptioner till övriga aktieägare. Aktieägare i Cyxone kommer att erhålla en (1) teckningsoption av serie TO4 för varje tjugoåtta (28) aktier som innehas på avstämningsdagen. Källa: SIX AB om inget annat anges.

Duka fram engelska
vad djuren gor nar ingen stor

Diskussion och forum - följ diskussionerna i Cyxone AB på Shareville. 4.075. 000 units, där varje unit motsvarar en aktie och en teckningsoption av serie TO4.

The warrants will be issued free of charge. Som tidigare kommunicerats har Cyxone AB (publ) (“Cyxone” eller “Bolaget”) beslutat att tilldela en (1) teckningsoption av serie TO4 till Bolagets befintliga aktieägare för varje tjugoåtta (28) ägda aktier per avstämningsdagen den 19 november 2020. Cyxone AB (publ) (“Cyxone” eller “Bolaget”) har genomfört en riktad nyemission om 4 075 000 units, där varje unit motsvarar en (1) aktie och en (1) teckningsoption av serie TO4, till vissa utvalda investerare (den “Riktade Emissionen”). Teckningskursen i den Riktade Emissionen uppgick till 4,70 SEK per unit. Cyxone AB (publ) (”Cyxone” or the ”Company”) have carried out a directed issue of 4,075,000 units, where each unit consists of one (1) share and one (1) warrant of series TO4, to selected investors (“the Directed Issue”).